Iron deficiency anemia (ida) and iron deficiency (id): are alginates a good choise to improve oral iron bioavailability and safety?

Baldacci, Mara; Gervasi, Giovanni Battista; Bertini, Marco

doi:10.15761/jts.1000210

Cited by 3 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is a patented co-processed 1 to 1 ratio compound between FBC and Sodium Alginate by applying Spray-Drying technologies. 6 , 7 This compound (named Feralgine ® ) may represent product with a very interesting and attractive profile by improving metabolism and taste of FBC. 7 Furthermore, as FBC, FBCA results are also well tolerated and well absorbed in IDA patients with overt CD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Iron Deficiency Anemia Refractory to Conventional Therapy but Responsive to Feralgine® in a Young Woman with Celiac Disease

Talarico

Giancotti

Miniero

et al. 2021

IMCRJ

Self Cite

View full text Add to dashboard Cite

Iron, which is an important micronutrient in the human body may be deficient in people with celiac disease (CD). Iron deficiency anemia (IDA) may be the presenting feature of celiac disease, also in the absence of diarrhea or weight loss. The treatment of IDA in patient with CD is primarily a gluten-free-diet (GFD), but it is also very important oral iron supplementation until the iron stores have been restored. However, a frequent problem in CD is the poor tolerability and poor efficacy of oral iron preparations. A new product, consisting of the combination of Ferrous Bysglicinate Chelate and Sodium Alginate (Feralgine™), has been demonstrated to be more bioavailable and well tolerated in CD. We present a case report that showed a clear efficacy of this product in a form of IDA refractory to conventional therapy in a woman with CD and we demonstrated a clear increase of serum iron after administration of this new type of ferrous.

show abstract

Section: Introductionmentioning

confidence: 99%

“…6 , 7 This compound (named Feralgine ® ) may represent product with a very interesting and attractive profile by improving metabolism and taste of FBC. 7 Furthermore, as FBC, FBCA results are also well tolerated and well absorbed in IDA patients with overt CD. 9 …”

Section: Introductionmentioning

confidence: 99%

Iron Deficiency Anemia Refractory to Conventional Therapy but Responsive to Feralgine® in a Young Woman with Celiac Disease

Talarico

Giancotti

Miniero

et al. 2021

IMCRJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…To ameliorate its bioavailability, taste and tolerability, a new oral iron source named FERALGINE™ (FBC-A) has been recently developed [13,14]. This new molecule is a patented co-processed one-to-one ratio compound between FBC and Sodium Alginate (AA), obtainedby using a spray drying technology [15,16].…”

Section: Introductionmentioning

confidence: 99%

“…DMT1 receptor saturation could be a limit in oral iron bioavailability that could be exceeded by FBC-A. In fact, slowly availability of iron by FBC-A administration could result in DMT-1 unsaturation with the consequence of increasing iron bioavailability [13,14,[23][24][25]. FERALGINE™ a New Oral iron Compound DOI: http://dx.doi.org/10.5772/intechopen.100445…”

Section: Introductionmentioning

confidence: 99%

FERALGINE™ a New Oral iron Compound

Talarico¹,

Giancotti²,

Mazza³

et al. 2022

Iron Metabolism - A Double-Edged Sword

Self Cite

View full text Add to dashboard Cite

Management of iron deficiency (ID) and iron deficiency anemia (IDA) is primarily focused to remove, when possible, the underlying cause of ID; subsequently its treatment is primary focused on iron stores repletion. Ferrous sulphate (FS) remains the mainstay of treatment and it is recommended as the first-line treatment of ID and IDA in children as in adults by all guidelines of scientific societies. However the effectiveness of FS is largely compromised by increased adverse effects, poor compliance and discontinuation of treatment. A new oral iron source named FERALGINE™ (FBC-A) has been recently developed. This new molecule is a patented co-processed one-to-one ratio compound between Ferrous Bysglicinate Chelate (FBC) and Sodium Alginate (AA), obtained by using a spray drying technology. The data presented in this short review highlight the efficacy and safety of the treatment with FBC-A and support its use in adult patients with IDA. Furthermore the present review also provides preliminary evidence to suggest FBC-A as first-line treatment for ID/IDA in patients with celiac disease (CD) or inflammatory bowel diseases (IBD).

show abstract

Oral iron supplementation with Feralgine® in inflammatory bowel disease: a retrospective observational study

Vernero

Boano

Ribaldone

et al. 2019

Minerva Gastroenterol Dietol

View full text Add to dashboard Cite

Iron deficiency anemia (ida) and iron deficiency (id): are alginates a good choise to improve oral iron bioavailability and safety?

Cited by 3 publications

References 7 publications

Iron Deficiency Anemia Refractory to Conventional Therapy but Responsive to Feralgine® in a Young Woman with Celiac Disease

Iron Deficiency Anemia Refractory to Conventional Therapy but Responsive to Feralgine® in a Young Woman with Celiac Disease

FERALGINE™ a New Oral iron Compound

Oral iron supplementation with Feralgine® in inflammatory bowel disease: a retrospective observational study

Contact Info

Product

Resources

About